10-Q: Lakewood-Amedex Hits Nasdaq with $7.5M Capital Injection

Lakewood-Amedex Biotherapeutics reported a Q1 loss but successfully listed on Nasdaq and raised $6.8 million in net proceeds to fund operations through 2026.

Summary

• Reported a net loss of $923,291 for the quarter ended March 31, 2026, compared to a $539,617 loss in the prior year period.
• Maintained a cash balance of only $11,709 at the end of the quarter, though liquidity significantly improved post-quarter.
• Successfully completed a $7.5 million Series C Convertible Preferred Stock private placement on April 21, 2026.
• Achieved a listing on the Nasdaq Capital Market on April 23, 2026, under the symbol LABT.
• Lead product candidate Nu-3, a broad-spectrum antimicrobial, is preparing for Phase 2a and Phase 2b clinical trials for diabetic foot ulcers.
• Total accumulated deficit reached $54.3 million as of March 31, 2026.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as a high-risk speculative situation. While the Nasdaq listing and $6.8M net raise provide a temporary lifeline, the company's extremely low cash at quarter-end and material internal control weaknesses remain significant red flags.

Positives

• Secured $6.8 million in net proceeds from the Series C financing in April 2026.
• Eliminated $1.5 million in convertible debt through automatic conversion into common stock upon Nasdaq listing.
• Converted all Series A and Series B Preferred Stock into common stock, simplifying the capital structure.
• Holds a robust intellectual property portfolio with 68 issued patents and 36 pending applications.
• Secured clinical manufacturing and research agreements with Pace Life Sciences and PERI to advance the Nu-3 program.

Negatives

• Widening net loss of $0.92 million for the quarter, up from $0.54 million year-over-year.
• Zero revenue generated as all products remain in clinical development.
• Identified material weaknesses in internal controls over financial reporting, including limited segregation of duties and IT control deficiencies.
• Current cash runway is only estimated to last through the end of 2026, necessitating further capital raises.
• General and administrative expenses increased by 89% to $703,444 due to listing and professional fees.

Risks

• Substantial doubt exists regarding the ability to continue as a going concern without additional funding beyond 2026.
• Clinical trial risks: Advancement of product candidates is entirely dependent on FDA approval and successful Phase 2/3 outcomes.
• Internal control weaknesses could lead to inaccurate financial reporting or failure to prevent fraud.
• The Series C Preferred Stock includes a variable conversion feature that could result in significant dilution if the share price declines.
• Highly competitive market for antimicrobial treatments with significant regulatory hurdles.

Future Outlook

The company expects its current cash and cash equivalents, bolstered by the April 2026 Series C financing, to be sufficient to fund operating requirements through the end of 2026. Future milestones include the initiation of a Phase 2a safety and dose response study for Nu-3 and further characterization of early-stage pipeline compounds.

Management Comments

• Management identified material weaknesses in internal controls over financial reporting as of March 31, 2026.
• The company intends to seek additional funding through equity, debt, or strategic arrangements to execute its business plan beyond 2026.
• The Nasdaq listing was a strategic move to align valuation and satisfy listing requirements following the conversion of outstanding securities.

Industry Context

StockSavvy.ai notes that Lakewood-Amedex is operating in the high-stakes antimicrobial resistance (AMR) sector, where the clinical need is massive but commercial pathways are often challenging. The successful Nasdaq listing provides a critical platform for visibility, but the company faces stiff competition from both established pharma and other biotech firms developing novel antibiotics.

Comparison to Industry Standards

• Like many clinical-stage biotechs such as Paratek Pharmaceuticals or Entasis Therapeutics, Lakewood-Amedex is currently pre-revenue and heavily reliant on capital markets.
• The $7.5 million raise is relatively small compared to mid-cap biotech standards, suggesting a lean operational model or a 'bridge' financing strategy.
• The use of variable-priced convertible preferred stock is a common but dilutive financing tool for micro-cap companies seeking Nasdaq qualification.

Management Changes

Corporate Governance

Legal Proceedings

• No material legal proceedings are currently outstanding.

Related Party Transactions

• Issued $125,000 in short-term promissory notes to existing shareholders and a director in Q1 2026.
• Issued a $43,158 short-term note to a director in April 2026.
• All related party short-term notes were repaid in full following the Series C financing.

Stakeholder Impact

• Shareholders face potential dilution from the conversion of Series C Preferred Stock, especially if the stock price falls toward the $1.00 floor.
• Creditors saw a reduction in risk as $1.5 million in convertible debt was converted to equity.
• Clinical partners (Pace and PERI) have secured commitments for upcoming manufacturing and trial services.

Next Steps

• Initiate Phase 2a safety and dose response study for Nu-3 topical gel.
• Execute Phase 2b dose comparative study to identify Phase 3 dosing.
• Implement remediation measures for identified material weaknesses in internal controls.
• Seek additional funding sources before the end of 2026.

Key Dates

Recommendation

The company has successfully navigated the Nasdaq listing and secured enough cash to survive the year, but the fundamental risks of clinical-stage biotech and the dilutive nature of the Series C stock suggest a cautious approach until Phase 2 data is available.

Keywords

Biotechnology, Antimicrobial Resistance, Nasdaq Listing, Diabetic Foot Ulcers, Series C Financing, Clinical Trials, Bisphosphocin, MRSA, Biopharmaceutical